Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall J Bateman

Showing results (171-180 of 391) with videos related to

Pageof 40
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
Nature Communications|May 22, 2019
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progressionFilip Liebsch, Luka Kulic, Charlotte Teunissen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisMaulikkumar P Patel, Arda Cetin, Matthew Johnson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic InterpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Journal of the International Neuropsychological Society : JINS|September 5, 2022
Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's diseaseJessica Nicosia, Andrew J Aschenbrenner, David A Balota, et al.
Molecular Neurodegeneration|May 2, 2021
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysisTim West, Kristopher M Kirmess, Matthew R Meyer, et al.
Alzheimer'S Research & Therapy|May 25, 2023
Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [<sup>18</sup>F]flortaucipir studyAntoinette O'Connor, David M Cash, Teresa Poole, et al.
The New England Journal of Medicine|November 30, 2022
Lecanemab in Early Alzheimer's DiseaseChristopher H van Dyck, Chad J Swanson, Paul Aisen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 2, 2023
Chronic GCPII (glutamate-carboxypeptidase-II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaquesShveta Bathla, Dibyadeep Datta, Feng Liang, et al.
Cell Stem Cell|June 6, 2022
Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neuronsLucia S Capano, Chihiro Sato, Elena Ficulle, et al.
Pageof 40

Showing results (171-180 of 391) with videos related to

Sort By:
Pageof 40
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
Nature Communications|May 22, 2019
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progressionFilip Liebsch, Luka Kulic, Charlotte Teunissen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisMaulikkumar P Patel, Arda Cetin, Matthew Johnson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic InterpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Journal of the International Neuropsychological Society : JINS|September 5, 2022
Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's diseaseJessica Nicosia, Andrew J Aschenbrenner, David A Balota, et al.
Molecular Neurodegeneration|May 2, 2021
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysisTim West, Kristopher M Kirmess, Matthew R Meyer, et al.
Alzheimer'S Research & Therapy|May 25, 2023
Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [<sup>18</sup>F]flortaucipir studyAntoinette O'Connor, David M Cash, Teresa Poole, et al.
The New England Journal of Medicine|November 30, 2022
Lecanemab in Early Alzheimer's DiseaseChristopher H van Dyck, Chad J Swanson, Paul Aisen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 2, 2023
Chronic GCPII (glutamate-carboxypeptidase-II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaquesShveta Bathla, Dibyadeep Datta, Feng Liang, et al.
Cell Stem Cell|June 6, 2022
Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neuronsLucia S Capano, Chihiro Sato, Elena Ficulle, et al.
Pageof 40